← Back to Search

Monoclonal Antibodies

LY3872386 for Atopic Dermatitis/Eczema

Phase 1
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 12 hours post dose on day 14 and day 30
Awards & highlights

Study Summary

This trial tests the safety and tolerance of an experimental drug, LY3872386, and prednisone in healthy people and people with atopic dermatitis. Blood tests will be used to study the body's response. The study lasts up to 85, 183, and 58 days for parts A, B, and C.

Who is the study for?
This trial is for healthy individuals and those with atopic dermatitis (eczema). Healthy participants must be of Japanese or Chinese descent as defined in the study, while those with eczema need to have struggled with current treatments. All must agree to use contraception if applicable.Check my eligibility
What is being tested?
The study tests LY3872386's safety and how it's processed by the body in both healthy people and those with eczema. Prednisone's safety will also be assessed in healthy subjects. The trial has three parts, each lasting different durations.See study design
What are the potential side effects?
Possible side effects include reactions typical of new medications such as skin irritation, digestive issues, changes in blood tests related to liver or kidney function, fatigue, and potential allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 12 hours post dose on day 14 and day 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 12 hours post dose on day 14 and day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and other non-serious adverse events (AEs) Considered by the Investigator to be Related to Study Drug Administration
Part B: Number of Participants with One or More TEAEs, SAEs and other non-serious AEs Considered by the Investigator to be Related to Study Drug Administration
Part C: Number of Participants with One or More TEAEs, SAEs and other non-serious AEs Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
Part A and B: Area Under the Concentration Versus Time Curve (AUC) of LY3872386
Part A and B: Maximum Observed Concentration (Cmax) of LY3872386
Part C: AUC of Prednisone and Prednisolone
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Part C: PrednisoneExperimental Treatment1 Intervention
Prednisone administered orally in healthy participants.
Group II: Part B: LY3872386Experimental Treatment1 Intervention
Multiple doses of LY3872386 administered either IV or SC in participants with atopic dermatitis.
Group III: Part A: LY3872386Experimental Treatment1 Intervention
Single doses of LY3872386 administered either intravenously (IV) or subcutaneously (SC) in healthy participants.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo administered either IV or SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prednisone
2014
Completed Phase 4
~2370

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,742 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,501 Total Patients Enrolled
~119 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top